|
End-of-day quote
Other stock markets
|
||
| - USD | - |
|
| 08-02 | Plus Therapeutics, Inc. will Change its Name to Cerenome | CI |
| 08-02 | Plus Therapeutics, Inc. will Change its Ticker to CNSY from PSTV | CI |
| Market Cap | 26.64M 23.15M 21.59M 19.84M 37.42M 2.54B 38.06M 254M 99.69M 1.27B 100M 97.84M 4.19B | P/E 2026 * |
-0.9x | P/E 2027 * | -1.47x |
|---|---|---|---|---|---|
| Enterprise Value | 26.64M 23.15M 21.59M 19.84M 37.42M 2.54B 38.06M 254M 99.69M 1.27B 100M 97.84M 4.19B | EV / Sales 2026 * |
4.23x | EV / Sales 2027 * | 1.39x |
| Free-Float |
98.02% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Cytori Therapeutics Inc
| Manager | Title | Age | Since |
|---|---|---|---|
Marc Hedrick
CEO | Chief Executive Officer | 64 | 2014-04-01 |
Andrew Sims
DFI | Director of Finance/CFO | 52 | 2020-02-05 |
Daniel Ortega
CTO | Chief Tech/Sci/R&D Officer | - | 2025-10-20 |
| Director | Title | Age | Since |
|---|---|---|---|
Marc Hedrick
BRD | Director/Board Member | 64 | 2002-09-30 |
Richard Hawkins
CHM | Chairman | 77 | 2018-01-24 |
| Director/Board Member | 66 | 2019-12-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.36% | +2.23% | -2.06% | +12.54% | 48.53B | |
| -2.71% | -3.58% | +398.09% | +456.59% | 39.87B | |
| -0.71% | +12.17% | +27.90% | +6.51% | 38.68B | |
| -0.71% | -3.72% | +4.94% | +65.34% | 35.13B | |
| -2.41% | +2.59% | +11.68% | +41.16% | 29.79B | |
| -0.66% | -4.67% | +35.50% | +124.56% | 16.11B | |
| -0.19% | -4.10% | - | - | 16.08B | |
| -0.62% | +2.02% | +2.76% | +14.08% | 13.61B | |
| -3.15% | -4.43% | -4.82% | -37.02% | 12.62B | |
| Average | -1.28% | +0.86% | +59.25% | +85.47% | 27.82B | |
| Weighted average by Cap. | -1.24% | +1.82% | +76.47% | +103.76% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 6.3M 5.47M 5.1M 4.69M 8.84M 600M 9M 60.12M 23.56M 299M 23.64M 23.12M 991M | 19.14M 16.63M 15.51M 14.25M 26.89M 1.82B 27.35M 183M 71.63M 910M 71.88M 70.3M 3.01B |
| Net income | -26.8M -23.29M -21.72M -19.96M -37.64M -2.55B -38.3M -256M -100M -1.27B -101M -98.43M -4.22B | -18.45M -16.04M -14.96M -13.74M -25.92M -1.76B -26.37M -176M -69.06M -877M -69.3M -67.78M -2.9B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
